Report Highlights

Genomics in cancer care at a turning point: Market Overview

The global genomics in cancer care market stood at USD 28.6 billion in 2024, propelled by accelerating adoption of next-generation sequencing across clinical oncology workflows. The market has transitioned decisively from research-grade application toward standard-of-care integration, with comprehensive genomic profiling now embedded in treatment guidelines for non-small cell lung cancer, breast cancer, and colorectal cancer across the United States, European Union, and Japan. Reimbursement expansion has been the single most consequential structural shift of the past three years, with CMS coverage of tumor sequencing under MolDX and equivalent European national health authority approvals unlocking institutional demand at scale previously constrained by payer resistance.

The current moment represents an inflection defined by three simultaneous forces: the maturation of liquid biopsy from experimental to reimbursable, the entry of AI-driven interpretation platforms that compress turnaround time from weeks to hours, and pharmaceutical industry mandates linking companion diagnostics to oncology drug approvals. Together, these forces are reshaping every node of the cancer diagnostic pathway. The market is no longer competing for oncologist awareness — it is competing for workflow integration, data ownership, and reimbursement positioning. This competitive restructuring is eliminating mid-tier players and concentrating value in platforms that combine sequencing hardware, bioinformatics infrastructure, and clinical reporting into integrated end-to-end solutions.

Key forces shaping genomics in cancer care growth

Three forces are driving revenue expansion with mechanistic precision. First, the proliferation of targeted oncology therapies has created inescapable demand for predictive biomarker testing. The FDA approved 19 biomarker-linked oncology therapies in 2023 alone, each requiring a validated companion diagnostic test before prescribing. This regulatory architecture converts genomic testing from an optional clinical enhancement into a mandatory reimbursable gateway, directly expanding test volumes and average selling prices. Oncology practices that cannot deliver biomarker results within five business days risk losing patients to specialized cancer centers — creating institutional pressure to upgrade sequencing infrastructure continuously.

Second, liquid biopsy platforms are extending the addressable market by enabling repeat testing during treatment, capturing minimal residual disease monitoring and resistance mutation tracking that tissue biopsy cannot practically serve. Third, AI-powered variant interpretation tools from companies including Tempus AI and Sophia Genetics are reducing the bioinformatics bottleneck that previously limited clinical uptake in community oncology settings. Community hospitals — representing more than 70% of US cancer diagnoses — are the fastest-growing demand segment, adopting cloud-connected sequencing platforms precisely because AI interpretation eliminates the need for in-house molecular pathology expertise. These three forces compound rather than compete, each expanding the revenue opportunity for platform providers across North America, Europe, and Asia Pacific simultaneously.

Barriers and risks in the genomics in cancer care market

The most structurally dangerous risk is reimbursement fragmentation, particularly in Europe, where national coverage decisions for comprehensive genomic profiling remain inconsistent across member states. Germany's AMNOG framework, France's INCa sequencing program, and the UK's Genomics England initiative operate under distinct coverage and pricing rules, forcing platform providers to negotiate 27 separate market access pathways for a single pan-European commercial strategy. This is not a cyclical inefficiency — it reflects permanently fragmented healthcare sovereignty and imposes a structural cost disadvantage on genomics companies relative to pharmaceutical counterparts who benefit from centralized EMA approval pathways.

The cyclical risk that poses the more immediate threat to growth in 2025–2026 is margin compression from sequencing hardware commoditization. Illumina's launch of the NovaSeq X at 50% lower cost per genome, combined with BGI's aggressive instrument placement strategy, is compressing reagent revenue per test. Because consumables represent 60–70% of NGS platform revenue, any acceleration in hardware commoditization directly erodes the recurring revenue streams that sustain platform valuations. This cyclical pressure is more dangerous to the near-term investment thesis than regulatory fragmentation, because it strikes the most profitable part of the business model precisely when the market is scaling fastest — exactly when investors expect margin expansion, not contraction.

Emerging opportunities in genomics in cancer care

The most credible near-term opportunity is minimal residual disease detection, which addresses the unmet clinical need for post-surgical and post-chemotherapy monitoring of cancer recurrence. Natera's Signatera platform has demonstrated that ctDNA-based MRD monitoring in colorectal cancer reduces unnecessary adjuvant chemotherapy, generating compelling health-economic data that payers are beginning to act on. The condition that must be met for this opportunity to fully materialise is prospective clinical utility evidence in two or three additional tumor types — breast and bladder cancer trials currently in Phase III will deliver that evidence by 2026, triggering coverage expansion across US and European markets simultaneously.

The second emerging opportunity is multi-cancer early detection, where Grail's Galleri test represents a commercially launched but underutilised platform with a viable path to population-scale deployment. The NHS-Grail MCED trial enrolling 140,000 participants will report interim results in 2026, and a positive outcome creates immediate policy justification for national screening program integration — a market expansion that transforms genomics from a diagnostic tool used after cancer diagnosis into a population health screening infrastructure used before symptoms emerge. Providers with existing laboratory logistics infrastructure, particularly Quest Diagnostics and Sonic Healthcare, are best positioned to capture volume rapidly if MCED gains screening-grade endorsement from oncology professional societies.

Investment case: Bull, bear, and what decides it

The bull case rests on three converging catalysts: mandatory companion diagnostic linkage to drug approvals expands the captive testing market by an estimated 18% annually through 2028; successful Phase III MRD monitoring data unlocks post-treatment surveillance as a new high-frequency testing category generating 3–4 tests per patient annually rather than one; and AI-driven interpretation platforms achieve cost-per-test reductions sufficient to accelerate community oncology adoption, expanding the effective market size by drawing in the 70% of US cancer patients currently managed outside major academic centers. Under this scenario, the market reaches USD 95 billion before 2034 and concentration increases as integrated platforms eliminate standalone sequencing-only vendors.

The bear case materialises if Illumina fails to defend its sequencing consumables revenue against BGI's instrument placement in emerging markets while simultaneously facing US antitrust-related competitive pressure. If pricing power erodes faster than volume scales — a realistic scenario given 20–30% annual cost-per-genome declines — platform revenues stagnate even as test volumes grow. Additionally, if payers respond to high genomic testing utilisation with utilization management restrictions, as occurred with BRCA testing following patent expiry, reimbursement rates for comprehensive genomic profiling could be cut by 30–40% within a single CMS annual fee schedule update, removing the financial incentive that currently drives institutional adoption.

The single swing variable is FDA's companion diagnostics linkage policy. If the FDA accelerates mandatory CDx requirements for all biomarker-linked oncology approvals — as signaled in its 2023 draft guidance on in vitro companion diagnostics — genomic testing volumes are locked into pharmaceutical development pipelines, creating protected multi-decade revenue streams that are insulated from price competition. If that policy is diluted, weakened, or slowed through regulatory deference to pharma industry lobbying for broader label indications without CDx mandates, the structural floor beneath the market's revenue growth disappears. The bull case does not require optimism about technology — it requires this one regulatory commitment to hold.

Market at a Glance

Regional performance: Where genomics in cancer care is growing fastest

North America remains the largest revenue contributor, accounting for an estimated 48% of global market revenue in 2024, driven by the depth of CMS reimbursement coverage, the density of National Cancer Institute-designated cancer centers, and the commercial maturity of US-based platform providers including Illumina, Foundation Medicine, and Guardant Health. The United States is the only market where liquid biopsy, comprehensive genomic profiling, and companion diagnostics are all simultaneously reimbursed at scale, making it structurally the highest average-selling-price environment globally. Canada lags the US by approximately five years in coverage depth but is closing that gap through provincial cancer agency adoption of NGS panels.

Asia Pacific is the fastest-growing region, expanding at an estimated 15.8% CAGR through 2034, led by China, Japan, and South Korea. China's National Reimbursement Drug List reforms have accelerated biomarker testing mandates for targeted therapies, while Japan's national genomic medicine implementation plan has driven rapid adoption of comprehensive cancer genome profiling in designated medical institutions. India represents a high-volume, low-realization opportunity where the absolute number of new cancer cases — over 1.4 million annually — creates structural demand, but pricing constraints limit revenue per test. Europe grows at a mid-range 10.2% CAGR, constrained by reimbursement fragmentation but supported by Germany's and France's genomic medicine national programs. Latin America and Middle East and Africa remain early-stage but will benefit from multi-cancer early detection program expansions post-2026.

Leading Market Participants

• Illumina
• Foundation Medicine
• Guardant Health
• Thermo Fisher Scientific
• Roche
• Natera
• Tempus AI
• BGI Genomics
• Grail
• Myriad Genetics

Where genomics in cancer care is headed by 2034

By 2034, the genomics in cancer care market reaches USD 89.4 billion and is defined by three structural characteristics: platform consolidation where the top five providers control over 65% of global revenue; AI-native interpretation infrastructure that makes genomic data actionable at the point of care without specialist intermediation; and multi-cancer early detection as a standard insurance-covered screening benefit in the United States, United Kingdom, and at least three major Asian markets. Comprehensive genomic profiling will have achieved standard-of-care status for all solid tumors in high-income countries, and liquid biopsy will be the dominant testing modality by volume, having displaced tissue biopsy as the first-line diagnostic for treatment selection and monitoring in the majority of cancer types.

Foundation Medicine, operating within the Roche ecosystem, is best positioned for 2034 because it controls both the diagnostic platform and the therapeutic pipeline data that will determine companion diagnostic partnerships for the next generation of targeted therapies. Guardant Health is the strongest independent operator, with liquid biopsy market leadership and a fully integrated MRD monitoring platform that positions it to capture the highest-frequency, highest-margin testing category in post-treatment surveillance. Tempus AI is the most strategically dangerous participant for incumbents — its real-world oncology dataset of over 7 million de-identified patient records creates a proprietary AI training asset that no new entrant can replicate, giving it durable competitive advantage in clinical decision support that extends far beyond sequencing hardware into software-driven revenue streams.

Market Segmentation

By Technology

• Next-Generation Sequencing
• Polymerase Chain Reaction
• Microarray
• In Situ Hybridization
• Liquid Biopsy Platforms
• Gene Expression Profiling

By Application

• Companion Diagnostics
• Tumor Mutational Burden Testing
• Minimal Residual Disease Monitoring
• Multi-Cancer Early Detection
• Pharmacogenomics
• Hereditary Cancer Risk Assessment

By Cancer Type

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Hematologic Malignancies
• Prostate Cancer
• Ovarian Cancer

By End User

• Academic and Research Institutes
• Hospital Laboratories
• Specialty Cancer Centers
• Pharmaceutical and Biotech Companies
• Contract Research Organizations

Frequently Asked Questions

Q1. What is the most reliable indicator that the genomics in cancer care market will sustain double-digit growth through 2034? ▼

The mandatory linkage between companion diagnostics and FDA oncology drug approvals creates a structurally protected testing mandate that grows in lockstep with the oncology drug pipeline, which currently contains over 1,800 active biomarker-stratified trials. This regulatory architecture is the strongest structural guarantor of sustained revenue growth available in any diagnostics market.

Q2. Which segment within genomics in cancer care offers the best risk-adjusted return for investors entering in 2025? ▼

Companion diagnostics co-development partnerships offer the best risk-adjusted return because FDA approval of a linked therapeutic creates 15-year exclusivity windows tied to drug labeling, insulating revenue from price competition. Investors should target agreements with mid-size oncology biotechs whose Phase II data already demonstrates biomarker stratification before Phase III confirmation.

Q3. How serious is the threat from Chinese genomics companies to Western platform margins? ▼

The threat is serious and immediate in emerging markets but limited in the United States and Europe by regulatory barriers — BGI's sequencing instruments face ITAR-equivalent restrictions in US federal procurement and increasing scrutiny from CFIUS on data sovereignty grounds. Western platform margins in North America and Europe are defensible for at least the next five years.

Q4. Is multi-cancer early detection a near-term revenue driver or a long-term structural shift? ▼

Multi-cancer early detection is a long-term structural shift with its first meaningful near-term catalyst arriving in 2026 when the NHS-Grail MCED trial reports, followed by a potential US preventive services task force review. Full revenue materialisation at population scale requires insurance coverage mandates that are realistically a 2028–2030 event in the US market.

Q5. Which region outside North America offers the strongest near-term market entry opportunity for genomics platform providers? ▼

Japan offers the strongest near-term entry opportunity because its national comprehensive cancer genome profiling implementation plan designates specific hospitals as sequencing centers with mandatory reimbursement from the national health insurance system, creating predictable institutional demand without the reimbursement negotiation risk present in China or India.